Summary of Key Information:

Reporting Period: Quarter and Year ended March 31, 2026

Nature of Filing / Announcement: Outcome of Board Meeting - Audited Financial Results

Audit Opinion:

Unmodified auditor's report issued by S K G N & Associates LLP, Statutory Auditors of the Company

Key Financial Highlights [Amounts in Indian Rupees Lakhs]:

Standalone Results:

For Year Ended March 31, 2026:

  • Revenue from Operations: ₹716.66 lakhs (compared to ₹590.02 lakhs in FY25 - 21.5% increase)
  • Total Income: ₹720.77 lakhs
  • Net Profit: ₹222.88 lakhs (compared to ₹186.34 lakhs in FY25 - 19.6% increase)
  • EPS: ₹3.59 (Basic and Diluted)
  • Other Equity: ₹11,287.14 lakhs
  • Cash and Cash Equivalents: ₹853.69 lakhs
  • Debt: ₹2,109.95 lakhs (borrowings)

For Quarter Ended March 31, 2026:

  • Revenue from Operations: ₹221.66 lakhs
  • Total Income: ₹223.43 lakhs
  • Net Profit: ₹77.31 lakhs
  • EPS: ₹1.24

Consolidated Results:

For Year Ended March 31, 2026:

  • Revenue from Operations: ₹1,043.57 lakhs (compared to ₹707.24 lakhs in FY25 - 47.5% increase)
  • Total Income: ₹1,048.88 lakhs
  • Net Profit: ₹244.89 lakhs (compared to ₹191.77 lakhs in FY25 - 27.7% increase)
  • EPS: ₹3.92 (Basic and Diluted)
  • Other Equity: ₹11,590.87 lakhs
  • Cash and Cash Equivalents: ₹878.57 lakhs
  • Debt: ₹2,307.48 lakhs (borrowings)

For Quarter Ended March 31, 2026:

  • Revenue from Operations: ₹303.51 lakhs
  • Total Income: ₹305.29 lakhs
  • Net Profit: ₹83.57 lakhs
  • EPS: ₹1.34

Segment-wise Performance:

The operating segment is identified as "Health Care Business" only. The Chief Operating Decision Maker reviews business performance at an overall company/group level as one segment.

Corporate Actions:

IPO Completion:

  • Completed Initial Public Offer of 20,886,200 equity shares of face value ₹5 each at issue price of ₹79 per share
  • Fresh issue of 11,392,500 equity shares aggregating ₹9,000.08 lakhs
  • Offer for sale of 9,493,700 equity shares by selling shareholder aggregating ₹7,500.02 lakhs
  • Listed on NSE and BSE on February 27, 2026

IPO Proceeds Utilization [as of March 31, 2026]:

  • Funding capital expenditure towards new IVF centers: ₹0.00 utilized out of ₹5,000.00 lakhs allocated
  • Repayment of outstanding loans: ₹0.00 utilized out of ₹2,000.00 lakhs allocated
  • General Corporate Purposes: ₹96.99 utilized out of ₹1,228.19 lakhs allocated
  • Fresh issue related expenses: ₹771.89 utilized out of ₹771.89 lakhs allocated
  • Total remaining unutilized: ₹8,131.20 lakhs

Other Significant Information:

  • Significant expenditure items exceeding 10% of total expenditure:
  • Sales and marketing expenses: ₹672.97 lakhs (Standalone FY26)
  • Rent: ₹231.76 lakhs (Standalone FY26)
  • Legal and professional fees: ₹265.83 lakhs (Standalone FY26)
  • Entities included in consolidation:
  • Holding Company: Gaudium IVF and Women Health Limited
  • Subsidiaries: Gaudium International Private Limited, EKK Global Private Limited (till August 05, 2025)